@CKD_ce Profile picture
Mar 9, 2022 45 tweets 48 min read Read on X
1) Welcome to our new #accredited #tweetorial on risk stratification to identify the patient with #T2D and #DKD most at risk for rapid progression to advanced CKD. I am Christos Argyropoulos MD, PhD (@ChristosArgyrop), Division Chief, Nephrology, @UNMHSC.
2) This #accredited #tweetorial series on #kidneydisease #DKD through the lens of #T2D is supported by an independent educational grant from the Boehringer Ingelheim/Lilly Alliance and is intended for healthcare providers.
3) This activity is accredited for #physicians #physicianassociates #nurses #NPs #pharmacists. Past programs still eligible for credit can be found at ckd-ce.com. Faculty disclosures are at ckd-ce.com/disclosures/. FOLLOW US for regular programs by expert faculty!
4) Let's start with a case!
Your 1st clinic appointment is a 68♀️ with long standing (15 years) Type 2 Diabetes (#T2D), complicated by retinopathy and Chronic Kidney Disease (#CKD). Her most recent laboratory data were obtained 3 months & 2 weeks prior to this visit:
5)
✔️estimated Glomerular Filtration Rate (eGFR) of 45, 52 ml/min/1.73m2
✔️Urine Albumin to Creatinine Ratio, UACR of 350 & 650 mg/g.
The patient is on Lisinopril 20mg/d, Rosuvastatin 20 mg & amlodipine 10mg. She asks you about her risk for further #CKD progression:
6) Before diving in the answer, let's define the risk factors for developing #CKD in patients with #T2D.
These have been defined as susceptibility, initiation & progression factors that affect hemodynamic, metabolic, inflammatory & fibrotic pathways
🔓doi.org/10.2215/CJN.11…
7) A conceptual model for the development of #CKD has been put forward based on observations in patients with Type 1 Diabetes. The timeline and the progression of events are less well delineated & the pattern not so clearcut in patients with #T2D 🔓doi.org/10.1016/j.kint…
8) The #UKDPS study has informed understanding of #CKD progression in #T2D:
➡️15 yrs after diagnosis, 40% of participants developed albuminuria
➡️30% developed eGFR< 60 ml/min per 1.73 m2 or doubling of the serum creatinine
🔓pubmed.ncbi.nlm.nih.gov/16731850/
🔓pubmed.ncbi.nlm.nih.gov/12472787/
9) While 60% of patients did not develop albuminuria during UKDPS , once *any* albuminuria developed, rates of events (whether death or progression of #CKD) were higher than those before the development of albuminuria.
👉Albuminuria is a major risk factor in #T2D
10) How should we assess albuminuria & integrate this lab test into our clinical risk assessment?
It all starts with a simple measurement!
👉Measurement of the urine albumin-to-creatinine ratio (#UACR) in an untimed urinary sample is the preferred screening strategy in #T2D
11) There are various ways to detect the presence of albuminuria & different clinical cutoffs that have been proposed to grade its severity.
The current laboratory 🔓academic.oup.com/clinchem/artic… & @goKDIGO 🔓kdigo.org/wp-content/upl… guidelines provide a handy ref for assays & cutoffs
12) Practice Points:
✔️ Prefer a quantitative over a dipstick test
✔️If a patient who has had previously normal values, develops UACR >30mg/g, the test should be repeated 2x over a 3-6mo period
✔️UACR 30-300mg/g ➡️moderate albuminuria
✔️UACR > 300 mg/g ➡️ severe proteinuria
13) How did we come with the recommendation to examine #UACR in an untimed First Morning Void (FMV) sample? Let’s nerd out with #RENAAL, one of the two trials that made Angiotensin Receptor Blockers (#ARBs) standard of care for #CKD in #T2D 🔓nejm.org/doi/full/10.10….
14) Data from the 701 participants in RENAAL were used to probe the predictive ability of different measures of proteinuria
🔓jasn.asnjournals.org/content/21/8/1…
✔️ (U)ACR in FMV
✔️Urine Albumin Concentration in FMV
✔️24hr Urine Albumin Excretion (UAE)
✔️24hr Urine Protein Excretion (UPE)
15) Key findings from this paper:
➡️ UACR (continuous and as quintiles) had the highest standardized hazard ratio for doubling serum creatinine (DSC, loss of ~50% kidney function) or End Stage Kidney (Renal) Disease #ESRD #ESKD
➡️ UACR had the highest AUC to predict #ESKD, DSC
16) RENAAL is not the only study that has linked measures of proteinuria/albuminuria with #CKD progression and #ESKD in patients with depressed eGFR. Enter the CRIC (Chronic Renal Insufficiency Cohort) Study: 🔓pubmed.ncbi.nlm.nih.gov/29784612/
👉Albuminuria determined BOTH outcomes
17) Using guideline & clinically relevant cutoffs of albuminuria (<30, 30-299, 300-999, >1,000mg/d):
✔️#ESKD rates were 7.4, 34.8, 78.7, 178.7 per 1,000 person-years (PYs)
✔️#CKD progression rates were 17.0, 61.4, 130.5, 295.1 per 1,000 PYs
✔️Loss of eGFR also tracked albuminuria
18) While the previous studies examined the baseline albuminuria as predictor of risk, the more relevant scenario for clinical practice is one in which multiple measurements of eGFR & baseline albuminuria are available for dynamic risk assessment about #CKD progression.
19) ➡️In an analysis led by @NavTangri proteinuria & the latest available eGFR were significant predictors of kidney failure
🔓pubmed.ncbi.nlm.nih.gov/27693260/
➡️A certain drop of eGFR by 25% within 1yr was associated w/ #ESKD in the CKD Prognosis Consortium
🔓academic.oup.com/ndt/article/27…
20) To sum up:
✔️Albuminuria (preferably measured as a FMV UACR) is a continuous measure of risk for #CKD progression among pts w/ #T2D
✔️Risk is particularly high for UACR > 300mg/g
✔️ eGFR (& changes in eGFR) are also associated with progression risk
It is now time to …
21) ... return to the patient from our clinical vignette, and use the @goKDIGO guideline "heatmap" kdigo.org/wp-content/upl… to assess her risk.
Her eGFR is between 45-60 ml/min/1.73m2 & UACR > 300mg/gm, thus putting her at VERY HIGH risk for #CKD progression (X in the chart).
22) Similar heatmaps also apply to the other risks associated with #CKD:
✔️All-cause Death
✔️Cardiovascular Death
✔️Progression of #CKD
✔️#ESKD/#ESRD
✔️Acute Kidney Injury
🔓kidney-international.org/article/S0085-…
But nowadays we can go beyond such semiquantitative risk stratification!
23) The Kidney Risk Failure Equation (#KRFE) were developed in patients with #CKD stages G3-5 in Canada (thanks @NavTangri) & subsequently validated in more than 700k patients from 30+ countries.
Available in smartphone apps (e.g. @QxMD) and the web kidneyfailurerisk.com
24) There are two versions of this risk calculator:
➡️4 Variable: Age, Sex, eGFR, UACR
➡️8 Variable. Which of the following is NOT one of the additional 4 variables in the 8-variable model?
25) Mark your answer and return tomorrow for more on risk stratification for #CKD among pts w/ #T2D and #DKD! You're earning CE/#CME!
Nods to @poyanmehr @GarySingerMD @iheartkidneys @GoggleDocs @MedTweetorials @GlomCon @ValleAlfonso @SantosGallegoMD @MunerMohamed1 @brendonneuen
26) Welcome back! We're talking about risk stratification for #T2D+#DKD to➡️#CKD. I am @ChristosArgyrop & you're earning CE/#CME! 👏 @dguerrot @kdjhaveri @AtulPathak31 @lissabauer @sophia_kidney @RpratleyMD @nephondemand @NephroWorldCup @edgarvlermamd @SeguraCardio @kamleshkhunti
27) Back to yesterday's closing poll. Scroll⬆️and COMMIT if you haven't already! The 8⃣-variable version of the Kidney Risk Failure Equation (#KRFE) includes 4 Variable + Calcium, Phosphorus, Bicarbonate, & *Serum* Albumin
28) ✔️Both formulas include an adjustment for geography
✔️ 8V formula may discriminate better
🔓jamanetwork.com/journals/jama/…
29) The KRFE quantifies the risk for our patient & allows us to discuss the next steps for managing her risk
✔️referral to Nephrology as her 5 year risk is > 3%
✔️team based care (if the 2 year risk > 10%)
✔️preparation for renal replacement (if the 2 year risk > 20%)
30) Having a number helps our patients understand their risks. But we can also use this number to *reduce* their risk. In this case (68👩‍🦳, with eGFR of 45 & UACR ~500mg/g), proteinuria is the only modifiable risk factor. If the latter were to ⬇️ 100mg/g, the KFRE yields:
31) ⬇️albuminuria➡️ ⬇️risk. Or should the patient assume that because she is taking guideline-based therapy (an Angiotensin Converting Enzyme Inhibitor #ACEi), she is protected from #CKD progression?
Key papers 🔓pubmed.ncbi.nlm.nih.gov/23506627/
🔓pubmed.ncbi.nlm.nih.gov/15149345/
to the rescue
32) What did these re-analyses of RENAAL, IDNT, OVERT show?
✔️Changes in albuminuria in the first 6mo of therapy predict long term response:
👉⬇️albuminuria by 50% ➡️⬇️#ESKD by 45%
👉risk⬇️ was continuously related to albuminuria⬇️
✔️risk highest in those with highest UACR
33) Upon reviewing the patient's chart, you find that the patient has never been prescribed > 20 mg of Lisinopril. The patient also has history of Acute Kidney Injury (#AKI) during a hospitalization for sepsis. Which of the following is true about her #CKD progression risk?
34) AKI, low eGFR & Albuminuria are ALL predictors of #CKD progression
🔓diabetesjournals.org/care/article/3…
✔️AKI⬆️risk by 247%
✔️Albuminuria⬆️risk by 423%
✔️⬇️eGFR by 10 ml/min/1.73m2⬆️risk by 22%
Maladaptive responses inside the kidney underline this nexus
🔓ncbi.nlm.nih.gov/labs/pmc/artic…
35) The dose of the background Inhibitor of the Renin Angiotensin System (#RASi) is an important predictor of #CKD progression.
The relevant preclinical observations were made >25 years ago: maximizing any RASi decreased production of fibrotic factors
🔓kidney-international.org/article/S0085-…
36) The Renoprotection of Optimal Antiproteinuric Doses (ROAD) study: effects of individualized maximization of ACEi or #ARB doses on #CKD progression & #ESKD.
Titration
👉risk⬇️by ~50%
👉proteinuria⬇️by ~20%
👉slower eGFR loss
👉no⬆️effect on BP
🔓jasn.asnjournals.org/content/18/6/1…
37) In meta-analyses, individualized maximization of the dose of the ACEi or ARB is associated with 22% ⬇️mortality in patients with #T2D against standard doses.
cochranelibrary.com/cdsr/doi/10.10…
38) Wrapping up the case of our patient w/ #T2D, she is at high risk for #CKD progression because of:
✔️residual albuminuria
✔️low eGFR
✔️submaximal dose of lisinopril
✔️prior AKI
What if albuminuria persists after⬆️lisinopril or if the patient can't tolerate the higher dose?
39) Patients with residual albuminuria while maxed on an inhibitor of the Renin Angiotensin System need additional therapies to⬇️their increased #CKD progression risk.
Which class of drugs have NOT yet been approved by @US_FDA for nephroprotection for such patients?
40) To date, #SGLT2i #flozins (#canagliflozin and #dapagliflozin) and novel, nonsteroidal #MRAs (#finerenone) have been approved as nephroprotective agents by enrolling patients with residual albuminuria, depressed eGFR on maximally tolerate doses of ACEis/ARBs.
41) Despite the high baseline renal risk (pts were albuminuric on maxed ACEi/ARB), #SGLT2i & nonsteroidal #MRA materially⬇️the risk for
✔️#CKD progression
✔️#ESKD
✔️#cardiovascular mortality
✔️hospitalization for heart failure
@Nephjc for maintaining the visual abstracts!
42) Take-home Points 1⃣:
💡Albuminuria (pre therapy, or residual after initiation of inhibitors of the Renin Angiotensin system) predicts risk for #CKD progression in pts w/ #T2D
✔️risk tools (KDIGO heatmap/KRFE) to visualize & quantitate risk when communicating with patients
43) Take-home Points 2⃣:
✔️Albuminuria (UACR in FMV) in pts before & after initiating tx w/ inhibitors of the Renin Angiotensin System
👉Patients w/ residual albuminuria after maxing RASi need further therapy to⬇️#CKD risk: #SGLT2i/#flozin & nonsteroidal MRA (finerenone)
44) And with that, you just earned 0.5hr CE/#CME! #physicians #physicianassociates #nursepractitioners #nurses #pharmacists Go to ckd-ce.com/dkd5/ to claim it. I am @ChristosArgyrop. FOLLOW US here & on @cardiomet_ce for more programs by expert authors in this space!
44) And with that, you just earned 0.5hr CE/#CME! #physicians #physicianassociates #nursepractitioners #nurses #pharmacists Go to ckd-ce.com/dkd5/ to claim it. I am @ChristosArgyrop. FOLLOW US here & on @cardiomet_ce for more programs by expert authors in this space!

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with @CKD_ce

@CKD_ce Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @ckd_ce

Feb 21, 2023
1) Welcome to this #accredited #tweetorial on genetic testing in the evaluation of patients with cystic kidney disease. #Kidney #cysts are a frequent finding, ranging from simple cysts to suspected or confirmed #ADPKD.
Expert author @dguerrot of @CHURouen 🇫🇷 leads us!
2) This program is supported by an educational grant from Otsuka Pharmaceuticals & is intended for #HCPs. #Physicians #Physicianassociates #nurses #nursepractioners #pharmacists 🇺🇸🇨🇦🇪🇺🇬🇧 earn CE/#CME credit. Statement of accreditation & faculty disclosures ckd-ce.com/disclosures
3a) Fortuitous discovery of non-malignant kidney cysts is increasingly frequent with age, and often leads to #nephrology referral.
Read 52 tweets
Jan 3, 2023
1) Welcome to our #accredited #tweetorial on clinical trial results and emerging data for treatment of Diabetes and CKD #DM in #CKD. I am Brian Rifkin MD, @brian_rifkin, from the Hattiesburg Clinic. #Nephtwitter #Medtwitter #FOAMed
2) This #accredited #tweetorial series on #kidneydisease #CKD is supported by an independent educational grant from the Boehringer Ingelheim/Lilly Alliance. It is not intended for US- or UK-based HCPs. Accreditation statement & faculty disclosures at ckd-ce.com/disclosures/.
3) This activity is accredited for #physicians #physicianassociates #nurses #NPs #pharmacists. Prior programs in this series, still eligible for CE/#CME, can be accessed at ckd-ce.com. FOLLOW US to learn from expert faculty!
Read 41 tweets
Oct 18, 2022
1) Welcome to this new #accredited #tweetorial on “Strategies to Apply Current Clinical Trial Data for SGLT2i to Reduce the Progression of CKD,” authored by our ⭐️tweetorialist Edgar V. Lerma 🇵🇭 @edgarvlermamd Image
2) This program is #accredited for CE/#CME #physicians #physicianassociates #nurses #pharmacists #nursepractitioners & is supported by an educational grant from the Boehringer Ingelheim Pharmaceuticals Inc and Eli Lilly Company. It is intended for healthcare professionals.
3) Faculty disclosures and statement of accreditation are provided at ckd-ce.com/disclosures/. Please FOLLOW @ckd_ce (& @cardiomet_CE!) so you don't miss ANY of our unique serialized #tweetorials, always 🆓, always from expert authors! Prior programs at ckd-ce.com/category/dkd/ .
Read 26 tweets
Sep 13, 2022
1) Welcome to a new #accredited (0.75h CE/#CME) #tweetorial on challenging case presentations for pts with #cardiometabolic disease, #CaReMe #FOAMed.
Our expert author is Claire Davies. @claireyrivs is a specialist diabetes & endocrinology #pharmacist working in Gateshead in 🇬🇧. Image
2) She is a member of UKCPA Diabetes & Endocrinology committee @UKCPADiabetes & works across #diabetes, #endocrinology, & emergency/acute care in Secondary Care. She is currently involved in development of regional guidelines & education to support medicines optimisation for PLWD
3a) This program is intended for healthcare professionals and is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly Company.
Read 36 tweets
Sep 7, 2022
1) Welcome to our new #accredited #tweetorial on the Pathophysiology of #DKD in #T2D: Traditional Teaching and New Insights. Our expert author is Hans-Joachim Anders, MD, @hjanders_hans from @LMU_Uniklinikum of @LMU_Muenchen
2) This #accredited #tweetorial series on the foundations of #kidneydisease #DKD through the lens of #T2D is supported by an independent educational grant from the Boehringer Ingelheim/Lilly Alliance and is intended for healthcare providers.
3) This activity is accredited for #physicians #physicianassociates #nurses #NPs #pharmacists. Past programs still eligible for credit can be found at ckd-ce.com. Faculty disclosures & accreditation statement are at ckd-ce.com/disclosures/. FOLLOW US!
Read 48 tweets
Aug 23, 2022
1a) Welcome to one of our favorite events on the @academiccme #accredited #tweetorial feeds: a takeover of our programming from @GoggleDocs! The focus of this tweetorial is data from #ADA2022 on #SGLT2i beyond cardiac disease. Our expert author is @GoggleDocs' @drpatrickholmes. Image
1b) Check out our other #ADA2022 recap #tweetorial by new @GoggleDocs family member @Ines_VFonseca who focused on the cardiac data presented: ckd-ce.com/dkd13_ada22a/
2) This program is #accredited for CE/#CME #physicians #physicianassociates #nurses #pharmacists #nursepractitioners & is supported by an educational grant from the Boehringer Ingelheim Pharmaceuticals Inc and Eli Lilly Company. It is intended for healthcare professionals.
Read 59 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(